

## OYC骨代謝関連製品掲載論文(共同研究を含む)

### Recombinant Human sRANKL

Cat. No. 47187000

#### 論文

Kawakami M, Yasuda H, Nishida D, Katakura A, Mizoguchi T. Development of a method for the identification of receptor activator of nuclear factor- $\kappa$ B + populations in vivo., *J Oral Biosci*, 63: 45-51, 2021

Yasuda H. Discovery of the RANKL/RANK/OPG system. *J Bone Miner Metab*. 39, 2-11, 2021

Takakura N, Matsuda M, Khan M, Hiura F, Aoki K, Hirohashi Y, Mori K, Yasuda H, Hirata M, Kitamura C, Jimi E. A novel inhibitor of NF- $\kappa$ B-inducing kinase prevents bone loss by inhibiting osteoclastic bone resorption in ovariectomized mice. *Bone*. 2020 135:115316.

Kobayakawa M, Matsubara T, Mizokami A, Hiura F, Takakura N, Kokabu S, Matsuda M, Yasuda H, Nakamura I, Takei Y, Honda H, Hosokawa R, Jimi E. Kif1c regulates osteoclastic bone resorption as a downstream molecule of p130Cas. *Cell Biochem Funct*. 2020 38:300-308.

Touyama K, Khan M, Aoki K, Matsuda M, Hiura F, Takakura N, Matsubara T, Harada Y, Hirohashi Y, Tamura Y, Gao J, Mori K, Kokabu S, Yasuda H, Fujita Y, Watanabe K, Takahashi Y, Maki K, Jimi E. Bif-1/Endophilin B1/SH3GLB1 regulates bone homeostasis. *J Cell Biochem*. 2019 120:18793-18804.

Tsukasaki M, Hamada K, Okamoto K, Nagashima K, Terashima A, Komatsu N, Win SJ, Okamura T, Nitta T, Yasuda H, Penninger JM, Takayanagi H. LOX Fails to Substitute for RANKL in Osteoclastogenesis. *J Bone Miner Res*. 2017; 32: 434-439.

Omata Y, Yasui T, Hirose J, Izawa N, Imai Y, Matsumoto T, Masuda H, Tokuyama N, Nakamura S, Tsutsumi S, Yasuda H, Okamoto K, Takayanagi H, Hikita A, Imamura T, Matsuo K, Saito T, Kadono Y, Aburatani H, Tanaka S. Genomewide comprehensive analysis reveals critical cooperation between Smad and c-Fos in RANKL-induced osteoclastogenesis. *J Bone Miner Res*. 30: 869-877, 2015

Enoki Y, Sato T, Tanaka S, Iwata T, Usui M, Takeda S, Kokabu S, Matsumoto M, Okubo M, Nakashima K, Yamato M, Okano T, Fukuda T, Chida D, Imai Y, Yasuda H, Nishihara T, Akita M, Oda H, Okazaki Y, Suda T, Yoda T. Netrin-4 derived from murine vascular endothelial cells inhibits osteoclast differentiation in vitro and prevents bone loss in vivo. *FEBS Lett*. 588: 2262-2269, 2014

Kuchimaru T, Hoshino T, Aikawa T, Yasuda H, Kobayashi T, Kadonosono T, Kizaka-Kondoh S. Bone resorption facilitates osteoblastic bone metastatic colonization by cooperation of insulin-like growth factor and hypoxia. *Cancer Sci*. 105: 553-559, 2014

Taniguchi R, Fukushima H, Osawa K, Maruyama T, Yasuda H, Weih F, Doi T, Maki K, Jimi E. RelB-induced expression of Cot, an MAP3K family member, rescues RANKL-induced osteoclastogenesis in alymphoplasia mice by promoting NF- $\kappa$ B2 processing by IKK $\alpha$ . *J Biol Chem*. 289: 7349-7361, 2014

Yasuda H. RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases. *World J Orthop*. 4: 207-217, 2013

Nagai Y, Osawa K, Fukushima H, Tamura Y, Aoki K, Ohya K, Yasuda H, Hikiji H, Takahashi M, Seta Y, Seo S, Kurokawa M, Kato S, Honda H, Nakamura I, Maki K, Jimi E. p130Cas, Crk-Associated Substrate, Plays Important Roles in Osteoclastic Bone Resorption 2013, 28, 2449-2462

Nakamura H, Aoki K, Masuda W, Alles N, Nagano K, Fukushima H, Osawa K, Yasuda H, Nakamura I, Mikuni-Takagaki Y, Ohya K, Maki K, Jimi E. Disruption of NF- $\kappa$ B1 prevents bone loss caused by mechanical unloading. *J Bone Miner Res*. 28, 1457-1467, 2013

Kikuta J, Wada Y, Kowada T, Wang Z, Sun-Wada GH, Nishiyama I, Mizukami S, Maiya N, Yasuda H, Kumanogoh A, Kikuchi K, Germain RN, Ishii M. Dynamic visualization of RANKL and Th17-mediated osteoclast function. *J Clin Invest*. 123: 866-873, 2013

Kotani M, Kikuta J, Klauschen F, Chino T, Kobayashi Y, Yasuda H, Tamai K, Miyawaki A, Kanagawa O, Tomura M, Ishii M. Systemic circulation and bone recruitment of osteoclast precursors tracked by using fluorescent imaging techniques. *J Immunol*. 190: 605-612. 2013

Hayashi SI, Murata A, Okuyama K, Shimoda Y, Hikosaka M, Yasuda H, Yoshino M. Stochastic differentiation into an osteoclast lineage from cloned macrophage-like cells. *Biochem Biophys Res Commun* 428: 303-308, 2012

Nakamichi Y, Mizoguchi T, Arai A, Kobayashi Y, Sato M, Penninger JM, Yasuda H, Kato S, DeLuca HF, Suda T, Udagawa N, Takahashi N. Spleen serves as a reservoir of osteoclast precursors through vitamin D-induced IL-34 expression in osteopetrotic op/op mice. *Proc Natl Acad Sci U S A.*, 109:10006-10011, 2012

Arai A, Mizoguchi T, Harada S, Kobayashi Y, Nakamichi Y, Yasuda H, Penninger JM, Yamada K, Udagawa N, Takahashi N. Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment. *J Cell Sci.*, 125: 2910-2917, 2012

Youn MY, Yokoyama A, Fujiyama-Nakamura S, Ohtake F, Minehata KI, Yasuda H, Suzuki T, Kato S, Imai Y. JMJD5, a JmjC-domain-containing protein, negatively regulates osteoclastogenesis through facilitating NFATc1 protein degradation., *J Biol Chem.*, 287: 12994-13004, 2012

Harada, S, Mizoguchi T, Kobayashi Y, Nakamichi Y, Takeda S, Sakai S, Takahashi F, Saito H, Yasuda H, Udagawa N, Suda T, Takahashi N. Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone., *J Bone Miner Res.* 27: 461-473, 2012

Kinugawa S, Koide M, Kobayashi Y, Mizoguchi T, Ninomiya T, Muto A, Kawahara I, Nakamura M, Yasuda H, Takahashi N, Udagawa N. Tetracyclines convert the osteoclastic-differentiation pathway of progenitor cells to produce dendritic cell-like cells., *J Immunol.*, 188: 1772-1781, 2012

Yasui T, Kadono Y, Nakamura M, Oshima Y, Matsumoto T, Masuda H, Hirose J, Omata Y, Yasuda H, Imamura T, Nakamura K, Tanaka S.: Regulation of RANKL-induced osteoclastogenesis by TGF- $\beta$  through molecular interaction between Smad3 and TRAF6., *J Bone Miner Res.*, 26: 1447-456, 2011

Hashiguchi D, Fukushima H, Nakamura M, Morikawa K, Yasuda H, Udagawa N, Maki K, Jimi E.: Mineral trioxide aggregate solution inhibits osteoclast differentiation through the maintenance of osteoprotegerin expression in osteoblasts., *J Biomed Mater Res A.* 96: 358-364, 2011

Maruyama T, Fukushima H, Nakao K, Shin M, Yasuda H, Weih F, Doi T, Aoki K, Alles N, Ohya K, Hosokawa R, Jimi E.: Processing of the NF-kappaB2 Precursor, p100, to p52 is Critical for RANKL-Induced Osteoclast Differentiation., *J Bone Miner Res.* 25: 1058-1067, 2010

Soysa NS, Alles N, Weih D, Lovas A, Mian AH, Shimokawa H, Yasuda H, Weih F, Jimi E, Ohya K, Aoki K.: The Pivotal Role of the Alternative NF-kappaB Pathway in Maintenance of Basal Bone Homeostasis and Osteoclastogenesis., *J Bone Miner Res.* 25: 809-818, 2010

Takada I, Tsuji N, Youn M-Y, Fujiyama S, Okada Maiko, Imai Y, Kondo S., Kitakawa H, Yasuda H, and Kato S: Purification and identification of estrogen receptor alpha co-regulators in osteoclasts, *Ann. N.Y. Acad. Sci.*, 1192: 201-207, 2010

Youn, M-Y, Takada I, Imai Y, Yasuda H, and Kato S.: Transcriptionally active nuclei are selective in mature multinucleated osteoclasts, *Genes to Cells*, 15: 1025-1035, 2010

Koide M, Kinugawa S, Ninomiya T, Mizoguchi T, Yamashita T, Maeda K, Yasuda H, Kobayashi Y, Nakamura H, Takahashi N, Udagawa N.: Diphenylhydantoin inhibits osteoclast differentiation and function through suppression of NFATc1 signaling., *J Bone Miner Res.*, 24: 1469-1480, 2009

Tomimori Y, Mori K, Koide M, Nakamichi Y, Ninomiya T, Udagawa N, Yasuda H: Evaluation of pharmaceuticals with a novel 50-hour animal model of bone loss., *J Bone Miner Res.*, 24: 1194-1205, 2009

Shinohara M, Koga T, Okamoto K, Sakaguchi S, Arai K, Yasuda H, Takai T, Kodama T, Morio T, Geha RS, Kitamura D, Kurosaki T, Ellmeier W, Takayanagi H.: Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals., *Cell*, 132: 794-806, 2008

Maruyama K, Takada Y, Ray N, Kishimoto Y, Penninger JM, Yasuda H, Matsuo K.: Receptor activator of NF-kappa B ligand and osteoprotegerin regulate proinflammatory cytokine production in mice., *J Immunol.*, 177: 3799-3805, 2006

## GST-RANKL-biotin

Cat. No. 47027000

### 論文

Kawakami M, Yasuda H, Nishida D, Katakura A, Mizoguchi T. Development of a method for the identification of receptor activator of nuclear factor- $\kappa$ B<sup>+</sup> populations in vivo., *J Oral Biosci*, 63: 45-51, 2021

Asano T, Okamoto K, Nakai Y, Tsutsumi M, Muro R, Suematsu A, Hashimoto K, Okamura T, Ehata S, Nitta T, Takayanagi H, Soluble RANKL is physiologically dispensable but accelerates tumour metastasis to bone. *Nat Metab*. 1: 868-875, 2019

Charles JF, Hsu L-Y, Niemi EC, Weiss A, Aliprantis AO, Nakamura MC, Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function., *J Clin Invest*, 122: 4592-4605, 2012

## Anti-Mouse RANKL Monoclonal Antibody (OYC1)

Cat. No. 47104001

### 論文

Mori T, Horibe K, Masanori Koide<sup>3</sup>, Uehara S, Yamamoto Y, Kato S, Yasuda H, Takahashi N, Udagawa N, Nakamichi Y. The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of  $1\alpha,25(\text{OH})_2\text{D}_3$  In Vivo. *Endocrinology*. 2020 Nov 1;161(11):bqaa178. doi: 10.1210/endocr/bqaa178.

Koide M, Yamashita T, Murakami K, Uehara S, Nakamura K, Nakamura M, Matsushita M, Ara T, Yasuda H, Penninger JM, Takahashi N, Udagawa N, Kobayashi Y. Sclerostin expression in trabecular bone is downregulated by osteoclasts. *Sci Rep*. 2020 Aug 13;10(1):13751. doi: 10.1038/s41598-020-70817-1.

Hayano H, Kuroshima S, Sasaki M, Tamaki S, Inoue M, Ishisaki A, Sawase T, Hayano H, et al. Distinct immunopathology in the early stages between different antiresorptives-related osteonecrosis of the jaw-like lesions in mice. *Bone*. 2020 Jun; 135:115308. doi: 10.1016/j.bone.2020.115308. Epub 2020 Mar 3. *Bone*. 2020. PMID: 32142911

Omiya T, Hirose J, Hasegawa T, Amizuka N, Omata Y, Izawa N, Yasuda H, Kadono Y, Matsumoto M, Nakamura M, Miyamoto T, Tanaka S. The effect of switching from teriparatide to anti-RANKL antibody on cancellous and cortical bone in ovariectomized mice. *Bone*. 2018 Feb;107:18-26

Okamatsu N, Sakai N, Karakawa A, Kouyama N, Sato Y, Inagaki K, Kiuchi Y, Oguchi K, Negishi-Koga T, Takami M. Biological effects of anti-RANKL antibody administration in pregnant mice and their newborns. *Biochem Biophys Res Commun*. 2017 Sep 23;491(3):614-621.

Koide M, Kobayashi Y, Yamashita T, Uehara S, Nakamura M, Hiraoka BY, Ozaki Y, Iimura T, Yasuda H, Takahashi N, Udagawa N. Bone Formation Is Coupled to Resorption Via Suppression of Sclerostin Expression by Osteoclasts. *J Bone Miner Res*. 2017 May 24. doi: 10.1002/jbmr.3175. [Epub ahead of print]

RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L, Lok SW, Mann GB; Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer (kConFab)., Rohrbach K, Huang LY, Soriano R, Smyth GK, Dougall WC, Visvader JE, Lindeman GJ. *Nat Med*. 2016 Aug;22(8):933-939.

Akiyama N, Takizawa N, Miyauchi M, Yanai H, Tateishi R, Shinzawa M, Yoshinaga R, Kurihara M, Demizu Y, Yasuda H, Yagi S, Wu G, Matsumoto M, Sakamoto R, Yoshida N, Penninger JM, Kobayashi Y, Inoue J, Akiyama T. Identification of embryonic precursor cells that differentiate into thymic epithelial cells expressing autoimmune regulator. *J Exp Med*. 2016 213: 1441-1458.

Kuroshima, S, Zeina Al-Salihi Z., Yamashita. Mouse anti-RANKL antibody delays oral wound healing and increases TRAP-positive mononuclear cells in bone marrow. *J Clin Oral Invest* 20:727-736, 2016

Kuroda Y, Maruyama K, Fujii H, Sugawara I, Ko SB, Yasuda H, Matsui H, Matsuo K. Osteoprotegerin Regulates Pancreatic  $\beta$ -Cell Homeostasis upon Microbial Invasion. *PLoS One*. 11(1):e0146544, 2016

Tohyama R, Kayamori K, Sato K, Hamagaki M, Sakamoto K, Yasuda H, Yamaguchi A. Establishment of a xenograft model to explore the mechanism of bone destruction by human oral cancers and its application to analysis of role of RANKL. *J Oral Pathol Med*. doi: 10.1111/jop.12376, 2015 (hRANKL中和抗体も使用)

Tokuyama N, Hirose J, Omata Y, Yasui T, Izawa N, Matsumoto T, Masuda H, Ohmiya T, Yasuda H, Saito T, Kadono Y, Tanaka S. Individual and combining effects of anti-RANKL monoclonal antibody and teriparatide in ovariectomized mice *Bone Reports* 2015, 2: 1-7

Akiyama T, Miyamoto Y, Yoshimura K, Yamada A, Takami M, Suzawa T, Hoshino M, Imamura T, Akiyama C, Yasuhara R, Mishima K, Maruyama T, Kohda C, Tanaka K, Potempa J, Yasuda H, Baba K, Kamijo R. Porphyromonas gingivalis-derived lysine gingipain enhances osteoclast differentiation induced by tumor necrosis factor- $\alpha$  and interleukin-1 $\beta$  but suppresses that by interleukin-17A: importance of proteolytic degradation of osteoprotegerin by lysine gingipain. *J Biol Chem*. 2014 : 289:15621-15630.

Funato S, Matsunaga A, Oh K, Miyamoto Y, Yoshimura K, Tanaka J, Suzuki D, Uyama R, Suzuki H, Mishima K, Nakamura M, Namiki O, Baba K, Inagaki K, Kamijo R. Effects of antibody to receptor activator of nuclear factor  $\kappa$ -B ligand on inflammation and cartilage degradation in collagen antibody-induced arthritis in mice. *J Negat Results Biomed*. 2014 Dec 12;13:18. doi: 10.1186/s12952-014-0018-0.

Yasuda H. RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases. *World J Orthop*. 4: 207-217, 2013

Sato K, Lee JW, Sakamoto K, Iimura T, Kayamori K, Yasuda H, Shindoh M, Ito M, Omura K, Yamaguchi A. RANKL Synthesized by Both Stromal Cells and Cancer Cells Plays a Crucial Role in Osteoclastic Bone Resorption Induced by Oral Cancer. *Am J Pathol*. 182, 1890-1899, 2013 (hRANKL中和抗体も使用)

Kikuta J, Wada Y, Kowada T, Wang Z, Sun-Wada GH, Nishiyama I, Mizukami S, Maiya N, Yasuda H, Kumanogoh A, Kikuchi K, Germain RN, Ishii M. Dynamic visualization of RANKL and Th17-mediated osteoclast function. *J Clin Invest*. 123: 866-873, 2013

Koide M, Kobayashi Y, Ninomiya T, Nakamura M, Yasuda H, Arai Y, Okahashi N, Yoshinari N, Takahashi N, Udagawa N. Osteoprotegerin-deficient male mice as a model for severe alveolar bone loss: comparison with RANKL-overexpressing transgenic male mice. *Endocrinology*. 154:773-782. 2013

Miyamoto, K., Yoshida S, Kawasumi M, Hashimoto K, Kimura T, Sato Y, Kobayashi T, Miyauchi Y, Hoshi H, Iwasaki R, Miyamoto H, Hao W, Morioka H, Chiba K, Kobayashi T, Yasuda H, Penninger JM, Toyama Y, Suda T, Miyamoto T. Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization., *J Exp. Med.*, 208: 2175-2181. 2011

Furuya, Y., Mori K, Ninomiya T, Tomimori Y, Tanaka S, Takahashi N, Udagawa N, Uchida K, Yasuda H. Increased bone mass in mice after single injection of anti-receptor activator of nuclear factor-kappaB ligand-neutralizing antibody: evidence for bone anabolic effect of parathyroid hormone in mice with few osteoclasts., *J Biol Chem.*, 286: 37023-37031, 2011 (mRANKL抗体OYC2も使用)

Soontrapa K, Honda T, Sakata D, Yao C, Hirata T, Hori S, Matsuoka T, Kita Y, Shimizu T, Kabashima K, Narumiya S.: Prostaglandin E2-prostaglandin E receptor subtype 4 (EP4) signaling mediates UV irradiation-induced systemic immunosuppression. *Proc Natl Acad Sci U S A*. 108: 6668-6673, 2011

Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ, Lindeman GJ, Visvader JE.: Control of mammary stem cell function by steroid hormone signalling., *Nature* 465: 798-802, 2010

## Anti-Human RANKL Monoclonal Antibody

Cat. No. 47102000

### 論文

Tohyama R, Kayamori K, Sato K, Hamagaki M, Sakamoto K, Yasuda H, Yamaguchi A. Establishment of a xenograft model to explore the mechanism of bone destruction by human oral cancers and its application to analysis of role of RANKL. *J Oral Pathol Med.* doi: 10.1111/jop.12376, 2015 (hRANKL中和抗体も使用)

Sato K, Lee JW, Sakamoto K, Iimura T, Kayamori K, Yasuda H, Shindoh M, Ito M, Omura K, Yamaguchi A. RANKL Synthesized by Both Stromal Cells and Cancer Cells Plays a Crucial Role in Osteoclastic Bone Resorption Induced by Oral Cancer. *Am J Pathol.* 182, 1890-1899, 2013

## 分化誘導ペプチドW9

Cat. No. 47025000

### 論文

Yasuda H. Discovery of the RANKL/RANK/OPG system. *J Bone Miner Metab.* 39, 2-11, 2021

Nakamura M, Nakamichi Y, Koide M, Yamashita T, Ara T, Nakamura H, Penninger JM, Furuya Y, Yasuda H, Udagawa N (2017) The W9 peptide directly stimulates osteoblast differentiation via RANKL signaling. *59:146-151*

Ozaki Y, Koide M, Furuya Y, Ninomiya T, Yasuda H, Nakamura M, Kobayashi Y, Takahashi N, Yoshinari N, Udagawa N. Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis. *PLoS One.* 2017 Sep 22;12(9):e0184904. doi: 10.1371/journal.pone.0184904. eCollection 2017.

Sawa M, Wakitani S, Kamei N, Kotaka S, Adachi N, Ochi M. Local administration of WP9QY (W9) peptide promotes bone formation in a rat femur delayed-union model. *J Bone Miner Metab.* 2017 Jun 28. doi: 10.1007/s00774-017-0852-5. [Epub ahead of print]

Khan A, Alles N, Soysa NS, Mamun M, Nagano K, Mikami R, Furuya Y, Yasuda H, Ohya K, Aoki K. The local administration of TNF- $\alpha$  and RANKL antagonist peptide promotes BMP-2-induced bone formation. *J Oral Biosci* 55: 47-54, 2013

Furuya Y, Inagaki A, Khan M, Mori K, Penninger JM, Nakamura M, Udagawa N, Aoki K, Ohya K, Uchida K, Yasuda H. Stimulation of bone formation in cortical bone of mice treated with a receptor activator of nuclear factor- $\kappa$ B ligand (RANKL)-binding peptide that possesses osteoclastogenesis inhibitory activity. *J Biol Chem*, 288: 5562-5571, 2013

Masud Khan AA, N, Soysa NS, Mamun M, Nagano K, Mikami R, Furuya Y, Yasuda H, Ohya K, Aoki K. The local administration of TNF- $\alpha$  and RANKL antagonist peptide promotes BMP-2-induced bone formation. *J Oral Biosci* 55: 47-54, 2013

Sugamori Y, Mise-Omata S, Maeda C, Aoki S, Tabata Y, Murali R, Yasuda H, Udagawa N, Suzuki H, Honma M, Aoki K. Peptide drugs accelerate BMP-2-induced calvarial bone regeneration and stimulate osteoblast differentiation through mTORC1 signaling. *Bioessays.* 2016 Jun 27. doi: 10.1002/bies.201600104.